 |
| 동국제약 본사 전경 (사진=동국제약) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Dongkuk Pharmaceutical announced on the 9th that its sales and operating profit were 661.6 billion won and 72.7 billion won based on consolidated financial statements in 2022, up 11.4% and 14.9%, respectively, from a year earlier.
By business sector, the company showed even growth in all divisions such as OTC, Overseas, ETC, Healthcare, and Dongguk Life Sciences (subsidiary).
The OTC (over-the-counter medicine) sector saw its sales grow year-on-year as demand for all brand products increased due to the influence of With Corona.
In the export (overseas business) sector, sales of Laureline Deposi, an anticancer drug used in prostate cancer and precocious puberty, grew significantly in Latin America, Mexico and Peru. In addition, the market share of Tycoplanin, an antibiotic raw material selected as a world-class product, is expanding in Turkey, Brazil and Japan.
In the healthcare sector, it has recorded even growth in all businesses, including beauty business (cosmetics), living health, and online.
The beauty business continues to grow in Japan's "Q10" and the U.S. "Amazon" as cosmetics brands maintain stable growth in Korea, the company said.
Its subsidiary, Dongguk Life Science, is growing its line of major contrast medium products represented by Famiray, Uniray and Duoray, and its line of medical devices such as image diagnostic equipment such as ultrasound and mobile CT, artificial intelligence (A.I) and in vitro diagnostic devices are growing evenly.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
